MiMedx Group/$MDXG
MiMedx Group falls after margin compression reports highlight net margin halving to 10.4% and warn that the fixed $125.38/cm2 Medicare reimbursement rate for 2026 may shrink its skin substitute market and pressure profitability.
10 hours agoLightyear AI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About MiMedx Group
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Ticker
$MDXG
Sector
Primary listing
Employees
837
Headquarters
Website
MiMedx Group Metrics
BasicAdvanced
$1.2B
29.47
$0.27
1.73
-
Price and volume
Market cap
$1.2B
Beta
1.73
52-week high
$9.71
52-week low
$5.79
Average daily volume
918K
Financial strength
Current ratio
4.405
Quick ratio
3.819
Long term debt to equity
7.047
Total debt to equity
7.623
Interest coverage (TTM)
28.41%
Profitability
EBITDA (TTM)
68.609
Gross margin (TTM)
81.99%
Net profit margin (TTM)
10.38%
Operating margin (TTM)
13.71%
Effective tax rate (TTM)
26.73%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
11.98%
Return on equity (TTM)
19.44%
Valuation
Price to earnings (TTM)
29.473
Price to revenue (TTM)
2.984
Price to book
4.93
Price to tangible book (TTM)
5.66
Price to free cash flow (TTM)
17.573
Free cash flow yield (TTM)
5.69%
Free cash flow per share (TTM)
0.453
Growth
Revenue change (TTM)
14.77%
Earnings per share change (TTM)
-47.92%
3-year revenue growth (CAGR)
14.68%
10-year revenue growth (CAGR)
8.44%
3-year earnings per share growth (CAGR)
-4.64%
10-year earnings per share growth (CAGR)
4.78%
What the Analysts think about MiMedx Group
Analyst ratings (Buy, Hold, Sell) for MiMedx Group stock.
Bulls say / Bears say
MiMedx’s Q2 2025 net sales rose 13% year-over-year to $98.6 million, comfortably above consensus estimates of $90.6 million, underscoring ongoing demand for its regenerative biomaterial products. (Reuters)
In Q3 2025, MiMedx delivered record revenue of $113.7 million—up 35% from a year earlier—driven by a 40% gain in wound-care products and a 26% increase in surgical portfolio sales. (Associated Press)
Adjusted EBITDA for Q2 2025 reached $24 million, representing 25% of net sales, reflecting healthy operating leverage as the company scales its commercial and manufacturing operations. (Reuters)
CMS’s proposed 2026 Physician Fee Schedule would reclassify skin substitutes—including MiMedx’s core EpiFix and AmnioFix products—as incident-to supplies with a single flat payment rate of $125.38 per square centimeter, potentially reducing Medicare reimbursement by up to 90% and posing a major revenue headwind. (CMS)
MiMedx’s selling, general and administrative expenses jumped 28% year-over-year to $69 million in Q3 2025 (47% of net sales), driven partly by legal and regulatory dispute costs, which could erode future margins if litigation persists. (GlobeNewswire)
Shares trade at approximately 23 times forward earnings, near the top of its historical multiple range, limiting upside if growth decelerates or market sentiment shifts. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
MiMedx Group Financial Performance
Revenues and expenses
MiMedx Group Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MiMedx Group stock?
MiMedx Group (MDXG) has a market cap of $1.2B as of November 07, 2025.
What is the P/E ratio for MiMedx Group stock?
The price to earnings (P/E) ratio for MiMedx Group (MDXG) stock is 29.47 as of November 07, 2025.
Does MiMedx Group stock pay dividends?
No, MiMedx Group (MDXG) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next MiMedx Group dividend payment date?
MiMedx Group (MDXG) stock does not pay dividends to its shareholders.
What is the beta indicator for MiMedx Group?
MiMedx Group (MDXG) has a beta rating of 1.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.